^
Association details:
| Biomarker: | EML4-ALK + ALK-PEX13 |
|---|---|
| Cancer: | Sarcoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Loss of 5'ALK leads to better response to crizotinib in sarcomas with ALK rearrangement
Published date:
05/19/2021
Excerpt:
Case #4 is an undifferentiated sarcoma with EML4-ALK fusion...All cases received and responded to Crizotinib therapy, with the Karnofsky Performance Status (KPS) improved from 30-60 score pre-therapy to 90-100 score after 3 months of Crizotinib.…Case#3 and #4, both retained the 5'ALK, relapsed at 9.4 m and 6.1 m…
DOI:
10.1200/JCO.2021.39.15_suppl.e23554
